20Med Therapeutics is a Dutch biomedical start-up active in the field of controlled drug delivery.
20Med has developed a unique portfolio of multifunctional polymer-based carriers (nanogels) for targeted delivery of small interfering RNAs (siRNAs) and microRNAs (miRNAs) for treatment of genetic diseases. The superior properties of the 20Med-nanogels above current siRNA delivery systems have been demonstrated in in-vitro and in-vivo experiments.
The company focus is to further develop and expand this proprietary set of unique polymeric hybrid constructs for RNAi application in a diversity of gene related diseases, and demonstrate their great potential for safe and efficient siRNA and miRNA based gene therapy in a clinical setting. 20Med therapeutics will establish cooperation with biotech- and pharma-companies that are addressing specific genetic diseases to meet their existing need for improved gene carrier systems for in vivo application.Visit website